KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial [Yahoo! Finance]
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Yahoo! Finance
rapid, well-tolerated on-demand treatment for 172 hereditary angioedema attacks in 33 children aged 2–11, a group that currently depends on injectable therapies. The trial, now the largest pediatric hereditary angioedema study, completed enrollment a year early and is expected to support a planned US pediatric new drug application in the third quarter of 2026, potentially bringing the first oral on-demand option to this underserved age group. We'll now examine how EKTERLY's early pediatric data and accelerated KONFIDENT-KID enrollment completion could influence KalVista's investment narrative and outlook. AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. KalVista Pharmaceuticals Investment Narrative Recap To own KalVista, you have to believe EKTERLY can become a leading oral option across hereditary angioedema, and t
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership ConferenceBusiness Wire
- KalVista Pharmaceuticals (KALV) had its price target raised by Stifel Nicolaus from $39.00 to $42.00. They now have a "buy" rating on the stock.MarketBeat
- KalVista Pharmaceuticals (KALV) had its price target lowered by Citizens Jmp from $29.00 to $28.00. They now have a "market outperform" rating on the stock.MarketBeat
- KalVista Pharmaceuticals (KALV) had its price target raised by Needham & Company LLC from $35.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
KALV
Earnings
- 3/25/26 - Miss
KALV
Sec Filings
- 3/27/26 - Form 4
- 3/25/26 - Form 10-KT
- 3/25/26 - Form 8-K
- KALV's page on the SEC website